Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 11:18 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

JAMA Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3%
February 28, 2025 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis today announced that it will present two posters at the 2025 AAD annual meeting which will take place in Orlando, FL, from March 7-11, 2025.
October 18, 2024 08:20 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis.
September 24, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.
May 14, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.
May 13, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Arcutis today announced that the JCAD published an evaluation of formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%.
March 04, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.
January 29, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
January 22, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

Arcutis today announced the launch of ZORYVE® (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis